Pakistan Journal of Pharmaceutical Sciences

Abstract: This research evaluated the clinical effectiveness of PVA eye drops in the treatment of post-cataract dry eye and their effects on tear levels of CCL1, IL-13 and IL-10. From January 2021 to January 2023, 100 patients with post-cataract dry eye were randomly assigned into control (conventional treatment) and study groups (conventional + PVA), 50 in each group. Outcome measures included symptom relief, stability of the tear film, Ocular Surface Disease Index (OSDI), cytokine levels (CCL1, IL-13, IL-10) and safety. The study group had a higher effective rate (96.0%) than controls (88.0%, P<0.05). Both groups had lower CCL1 and IL-13 and higher IL-10 after treatment, with greater responses in the PVA group (P<0.05). Tear breakup time, Schirmer's test, fluorescein staining and OSDI were similarly improved more in the PVA group. No side effects, such as burning, foreign body sensation, or congestion, were noted. These results confirm the application of PVA eye drops as tolerable and efficacious therapy for post-cataract surgery dry eye by improving tear film stability and modulating inflammatory cytokines.